Incremental benefits of repeated mesenchymal stromal cell administration compared with solitary intervention after myocardial infarction

Cytotherapy

Volumn 16, Issue 4, 2014, Pages 460-470

  Richardson, James D ^a,b,c   Psaltis, Peter J ^a,b,d   Frost, Lachlan ^a,b   Paton, Sharon ^c   Carbone, Angelo ^a,b   Bertaso, Angela G ^a,b   Nelson, Adam J ^a,b   Wong, Dennis T L ^a,b   Worthley, Matthew I ^a,b   Gronthos, Stan ^c   Zannettino, Andrew C W ^c   Worthley, Stephen G ^a,b,c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d MAYO CLINIC   (United States)

Author keywords

Cardiac magnetic resonance; Hypoxic conditioning; Mesenchymal stromal cells; Multiple intervention; Myocardial infarction; Optimization; Prospective isolation; Repair; Timing

Indexed keywords

ALLOGENEIC MESENCHYMAL STROMAL CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE SIZE; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; THERAPY EFFECT;

ANIMALIA; RATTUS;

CARDIAC MAGNETIC RESONANCE; HYPOXIC CONDITIONING; MESENCHYMAL STROMAL CELLS; MULTIPLE INTERVENTION; MYOCARDIAL INFARCTION; OPTIMIZATION; PROSPECTIVE ISOLATION; REPAIR; TIMING;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; RATS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84895827380     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.07.016     Document Type: Article

References (43)

1. Lipinski M.J., Biondi-Zoccai G.G.L., Abbate A., Khianey R., Sheiban I., Bartunek J., et al. Impact of intracoronary cell therapy on LV function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007, 50:1761-1767.
2. Richardson J.D., Nelson A.J., Zannettino A.C., Gronthos S., Worthley S.G., Psaltis P.J. Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step. Stem Cell Rev 2013, 9:281-302.
3. Psaltis P.J., Paton S., See F., Arthur A., Martin S., Itescu S., et al. Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. J Cell Physiol 2010, 223:530-540.
4. Das R., Jahr H., van Osch G.J., Farrell E. The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue Eng Part B Rev 2010, 16:159-168.
5. See F., Seki T., Psaltis P.J., Sondermeijer H.P., Gronthos S., Zannettino A.C.W., et al. Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. J Cell Mol Med 2011, 15:2117-2129.
6. Hu X., Yu S.P., Fraser J.L., Lu Z., Ogle M.E., Wang J.-A., et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 2008, 135:799-808.
7. van der Spoel T.I.G., Jansen of Lorkeers S.J., Agostoni P., van Belle E., Gyöngyösi M., Sluijter J.P.G., et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res 2011, 91:649-658.
8. Virag J.I., Murry C.E. Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. Am J Pathol 2003, 163:2433-2440.
9. Hawkins H.K., Entman M.L., Zhu J.Y., Youker K.A., Berens K., Doré M., Smith C.W. Acute inflammatory reaction after myocardial ischemic injury and reperfusion. Development and use of a neutrophil-specific antibody. Am J Pathol 1996, 148:1957-1969.
10. Thangarajah H., Vial I.N., Chang E., El-Ftesi S., Januszyk M., Chang E.I., et al. IFATS collection: adipose stromal cells adopt a proangiogenic phenotype under the influence of hypoxia. Stem Cells 2009, 27:266-274.
11. Kinnaird T., Stabile E., Burnett M.S., Lee C.W., Barr S., Fuchs S., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004, 94:678-685.
12. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008, 103:1204-1219.
13. Quevedo H.C., Hatzistergos K.E., Oskouei B.N., Feigenbaum G.S., Rodriguez J.E., Valdes D., et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A 2009, 106:14022-14027.
14. Richardson J.D., Bertaso A.G., Psaltis P.J., Frost L., Carbone A., Paton S., et al. Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction. J Card Fail 2013, 19:342-353.
15. Position of the American Heart Association on the use of research animals. A statement for health professionals from a task force appointed by the Board of Directors of the American Heart Association. Circ Res 1985, 57:330-331.
16. Richardson JD, Bertaso AG, Frost L, Psaltis PJ, Carbone A, Koschade B, et al. Cardiac magnetic resonance, transthoracic and transoesophageal echocardiography: a comparison of in vivo assessment of ventricular function in rats [published online ahead of print July 8, 2013]. Lab Anim.
17. Cerqueira M.D., Weissman N.J., Dilsizian V., Jacobs A.K., Kaul S., Laskey W.K., et al. American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. Circulation 2002, 105:539-542.
18. Dai W., Hale S.L., Martin B.J., Kuang J.-Q., Dow J.S., Wold L.E., et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium. Circulation 2005, 112:214-223.
19. Duan W.R., Garner D.S., Williams S.D., Funckes-Shippy C.L., Spath I.S., Blomme E.A. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 2003, 199:221-228.
20. Psaltis P.J., Carbone A., Nelson A.J., Lau D.H., Jantzen T., Manavis J., et al. Reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischemic cardiomyopathy. JACC Cardiovasc Interv 2010, 3:974-983.
21. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
22. Gronthos S., Zannettino A.C.W., Hay S.J., Shi S., Graves S.E., Kortesidis A., et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003, 116:1827-1835.
23. Nowosielski M., Schocke M., Mayr A., Pedarnig K., Klug G., Kohler A., et al. Comparison of wall thickening and ejection fraction by cardiovascular magnetic resonance and echocardiography in acute myocardial infarction. J Cardiovasc Magn Reson 2009, 11:22.
24. Abdel-Latif A., Bolli R., Tleyjeh I.M., Montori V.M., Perin E.C., Hornung C.A., et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007, 167:989-997.
25. Gnecchi M., He H., Melo L.G., Noiseaux N., Morello F., de Boer R.A., et al. Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells 2009, 27:971-979.
26. Friedenstein A.J., Chailakhjan R.K., Lalykina K.S. The development of fibroblastic colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Proliferation 1970, 3:393-403.
27. Pittenger M., Mackay A., Beck S., Jaiswal R., Douglas R., Mosca J., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
28. Schuleri K.H., Amado L.C., Boyle A.J., Centola M., Saliaris A.P., Gutman M.R., et al. Early improvement in cardiac tissue perfusion due to mesenchymal stem cells. Am J Physiol Heart Circ Physiol 2008, 294:H2002-H2011.
29. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2277-2286.
30. Poh K.-K., Sperry E., Young R.G., Freyman T., Barringhaus K.G., Thompson C.A. Repeated direct endomyocardial transplantation of allogeneic mesenchymal stem cells: safety of a high dose, "off-the-shelf," cellular cardiomyoplasty strategy. Int J Cardiol 2007, 117:360-364.
31. Dixon J.A., Gorman R.C., Stroud R.E., Bouges S., Hirotsugu H., Gorman J.H., et al. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation 2009, 120(11 Suppl):S220-S229.
32. Houtgraaf J.H., de Jong R., Kazemi K., de Groot D., van der Spoel T.I., Arslan F., et al. Intracoronary infusion of allogeneic mesenchymal precursor cells directly following experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling and improves cardiac function. Circ Res 2013, 113:153-166.
33. Ertl G., Frantz S. Healing after myocardial infarction. Cardiovasc Res 2005, 66:22-32.
34. Zhang M., Mal N., Kiedrowski M., Chacko M., Askari A.T., Popovic Z.B., et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 2007, 21:3197-3207.
35. Wollert K.C., Meyer G.P., Lotz J., Ringes Lichtenberg S., Lippolt P., Breidenbach C., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004, 364:141-148.
36. Meyer G.P., Wollert K.C., Lotz J., Steffens J., Lippolt P., Fichtner S., et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006, 113:1287-1294.
37. Traverse J.H., Henry T.D., Ellis S.G., Pepine C.J., Willerson J.T., Zhao D.X., et al. Cardiovascular Cell Therapy Research Network. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: The latetime randomized trial. JAMA 2011, 306:2110-2119.
38. Aggarwal S., Pittenger M. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
39. Psaltis P.J., Worthley S.G. Endoventricular electromechanical mapping-the diagnostic and therapeutic utility of the NOGA XP Cardiac Navigation System. J Cardiovasc Transl Res 2009, 2:48-62.
40. Gnecchi M., He H., Liang O.D., Melo L.G., Morello F., Mu H., et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005, 11:367-368.
41. Behfar A., Yamada S., Crespo-Diaz R., Nesbitt J.J., Rowe L.A., Perez-Terzic C., et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol 2010, 56:721-734.
42. Hare J.M., Fishman J.E., Gerstenblith G., DiFede Velazquez D.L., Zambrano J.P., Suncion V.Y., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308:2369-2379.
43. Bartunek J., Behfar A., Dolatabadi D., Vanderheyden M., Ostojic M., Dens J., et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 2013, 61:2329-2338.